Physician

Vinh-Linh B Nguyen, MD

According to 2025 Medicare claims, Vinh-Linh Nguyen, MD (NPI: 1285603639) practices hematology/oncology in the Bakersfield-Delano, CA market, with the plurality of this provider's patient population coming from Kern, CA. This provider's primary affiliated billing organization is BLOOD AND CANCER THERAPEUTICS A MEDICAL CORPORATION (NPI: 1679184535; TIN: 851526638) and primary practice location at 93306-7276. Nguyen is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Nguyen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 543 traditional Medicare patients, billed 668,937 HCPCS/CPT codes, and received $21,518,269 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,522 prescription claims across 312 beneficiaries totaling $4,121,455 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 192 claims. Open Payments data shows 14 records totaling $294. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $2,464,418 to $21,518,269. Similarly, Part D prescription costs have risen steadily, from $1,920,710 to $4,121,455. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,020 and ending at $1,935.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	419	198,660	$2,464,418
2016	408	224,917	$3,805,336
2017	435	238,325	$4,362,495
2018	455	247,266	$4,543,573
2019	467	269,695	$5,284,639
2020	410	228,910	$4,711,802
2021	471	252,709	$6,548,916
2022	503	381,816	$10,022,636
2023	542	511,295	$13,890,303
2024	543	668,937	$21,518,269

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	365	2,848	$1,920,710
2016	385	2,865	$2,528,601
2017	386	2,955	$2,623,474
2018	366	2,694	$2,680,387
2019	392	2,540	$2,331,351
2020	337	2,238	$3,215,257
2021	330	1,994	$2,701,181
2022	318	2,057	$3,883,220
2023	313	2,124	$3,179,750
2024	312	2,522	$4,121,455

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	232	$99,999
2016	N/R	206	$72,603
2017	N/R	30	$4,251
2018	N/R	35	$1,295
2019	N/R	N/R	N/R
2020	N/R	33	$2,052
2021	N/R	68	$3,900
2022	27	174	$5,967
2023	25	211	$36,715
2024	N/R	192	$6,132

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	278	497	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	382	883	$59
96361	Infusion into a vein for hydration, each additional hour	283	5,186	$9
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	249	4,773	$1
J7050	Infusion, normal saline solution, 250 cc	241	5,676	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	56	1,561	$724,619
Kisqali	Ribociclib Succinate	30	805	$556,530
Revlimid	Lenalidomide	34	931	$460,218
Xtandi	Enzalutamide	27	810	$366,089
Tagrisso	Osimertinib Mesylate	21	630	$361,889

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	57	$1,878
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	21	$1,445
J8700	Temozolomide, oral, 5 mg	N	N/R	15	$858
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	45	$847
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	17	$578

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$294	Dendreon Pharmaceuticals LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vinh-Linh B. Nguyen, MD?

Tedicare shows public-source Medicare data for Vinh-Linh B. Nguyen, MD (NPI 1285603639), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vinh-Linh B. Nguyen, MD have ACO affiliation data?

Vinh-Linh B. Nguyen, MD is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Vinh-Linh B. Nguyen, MD?

Vinh-Linh B. Nguyen, MD is linked to BLOOD AND CANCER THERAPEUTICS A MEDICAL CORPORATION (billing NPI 1679184535) in the available physician profile data.

Does Vinh-Linh B. Nguyen, MD have Open Payments data?

Vinh-Linh B. Nguyen, MD has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.